WAVE Life Sciences Ltd(WVE)stock report

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington’s disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.

Finance:
Market Cap:274.0M; Shares Outstanding:34.3M; Short Interest: 12.46%; Q3 2019(9/30/19): Cash 209M. Loss 50.86M

EPS and Sales:
https://finance.yahoo.com/quote/WVE/financials?p=WVE

Date EPS % last year % last quarter
2018.12.31 -5.06 -31.43% -36.90%
2019.3.31 -1.2927 -2.68% -74.45%
2019.6.30 -2.5139 -3.52% -94.47%
2019.9.30 -3.9926 -8.02% -58.82%

 

Date Sales % last year % last quarter
2018.12.31 14.41M 270.25% 33.55%
2019.3.31 3.03M 112.80% -78.97%
2019.6.30 10.65M 69.08% 251.49%
2019.9.30 13.58M 25.84% 27.51%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=WVE&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/WVE/institutional-ownership/

2019.12.31:
Total institutions: 110,no change
Shares hold: 32539.4k shares. no change
shares% hold: 94.90%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/WVE/price-targe

Leave a Reply